US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco S&P SmallCap Health Care ETF

52.32

+0.94611.84%

Post-market: 52.31-0.0057-0.01%19:30 EDT

Volume:5K

Turnover:245.27K

Market Cap:177.35M

PE:- -

High:52.34

Open:51.47

Low:51.47

Close:51.37

52wk High:56.45

52wk Low:39.08

Shares:3.39M

Float Shares:3.39M

Volume Ratio:0.39

T/O Rate:0.14%

Dividend:0.00

Dividend Rate:0.01%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Teva announces FDA approval for Weltruza

Alkermes Plc : Leerink Partners Cuts Target Price to $45 from $50

THOMSON REUTERS

Newron presses on with ENIGMA-TRS program as FDA clinical hold prompts safety review

Alkermes Advances Adult ADHD Pipeline With New Phase 2 Study

Novartis announces FDA approval of Rhapsido for symptomatic dermographism

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

Corcept Endocrinology President Sean Maduck Disposes of USD 2.89 Million in Corcept Therapeutics Shares

Corcept Files Form 3 for President, Corcept Endocrinology Justin Gunn

Missed BrightSpring’s 112% Run? The Argument Behind It Still Holds Curiosity

Simply Wall St.

Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $83,464.02

Alkermes (ALKS), What Is Behind The Fresh Attention?

Simply Wall St.

BrightSpring Health Updates Financial Calendar for Third-Quarter 2026 Results Release and Call

Teva announces FDA approval of Degevma as a biosimilar to Xgeva

Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M

Court Dismisses Molina Healthcare Securities Fraud Complaint, Allows Plaintiff to Amend

EBR Systems advances FDA approval process for new WiSE manufacturing site

Alkermes (ALKS) Gets a Hold from Goldman Sachs

Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches

Corcept Therapeutics Announces New Endocrinology Division President

Corcept Names Justin Gunn President of Endocrinology as Sean Maduck Retires

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/PSCH/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PSCH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSCH\",,,,,undefined,":{"symbol":"PSCH","market":"US","secType":"STK","nameCN":"Invesco S&P SmallCap Health Care ETF","latestPrice":52.3157,"timestamp":1791576000000,"preClose":51.3696,"halted":0,"volume":4712,"hourTrading":{"tag":"盘后","latestPrice":52.31,"preClose":52.3157,"latestTime":"19:30 EDT","volume":2,"amount":104.6457,"timestamp":1791588605489,"change":-0.0057,"changeRate":-0.000109,"amplitude":0},"delay":0,"changeRate":0.01841750763097243,"floatShares":3390000,"shares":3390000,"eps":0,"marketStatus":"Market Closed","change":0.9461,"latestTime":"10-09 16:00:00 EDT","open":51.47,"high":52.335,"low":51.47,"amount":245265.04236,"amplitude":0.016839,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":51.3696,"sharesOutstanding":3220000,"nav":51.36564,"aum":172588550.4,"dividendRate":0.000057,"bidAskSpread":0.001934,"postHourTrading":{"tag":"盘后","latestPrice":52.31,"preClose":52.3157,"latestTime":"19:30 EDT","volume":2,"amount":104.6457,"timestamp":1791588605489,"change":-0.0057,"changeRate":-0.000109,"amplitude":0},"volumeRatio":0.390461,"impliedVol":0.1344,"impliedVolPercentile":0.8606},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSCH\",,,,,undefined,":{"symbol":"PSCH","floatShares":3390000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.390461,"shares":3390000,"dividePrice":0.003,"high":52.335,"amplitude":0.016839,"preClose":51.3696,"low":51.47,"week52Low":39.08,"pbRate":"--","week52High":56.454,"institutionHeld":0,"latestPrice":52.3157,"eps":0,"divideRate":0.000057,"volume":4712,"delay":0,"ttmEps":0,"open":51.47,"prevYearClose":44.0553,"prevWeekClose":51.6331,"prevMonthClose":52.07,"prevQuarterClose":52.07,"fiveDayClose":51.6331,"twentyDayClose":52.9516,"sixtyDayClose":53.5547},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSCH\",params:#limit:5,,,undefined,":[{"date":"2026-03-23","symbol":"PSCH","amount":0.00033,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-09-22","symbol":"PSCH","amount":0.00259,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"PSCH","amount":0.00199,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-24","symbol":"PSCH","amount":0.01419,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-24","defaultRemindTime":1742823000000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-24","currency":"USD","dateTimestamp":1742788800000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSCH","amount":0.01801,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-27","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSCH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-30","value":0.01949,"currency":"USD"},{"executeDate":"2018-09-24","recordDate":"2018-09-25","paymentDate":"2018-09-28","value":0.00522,"currency":"USD"},{"executeDate":"2022-03-31","recordDate":null,"paymentDate":"2022-03-31","value":3,"currency":"USD"},{"executeDate":"2023-12-18","recordDate":"2023-12-19","paymentDate":"2023-12-22","value":0.00448,"currency":"USD"},{"executeDate":"2024-03-18","recordDate":"2024-03-19","paymentDate":"2024-03-22","value":0.03613,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSCH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSCH\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674785642","title":"Teva announces FDA approval for Weltruza","url":"https://stock-news.laohu8.com/highlight/detail?id=2674785642","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674785642?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:05","pubTimestamp":1791543924,"startTime":"0","endTime":"0","summary":"Teva (TEVA) announced that the FDA has approved Weltruza for extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-for-weltruza-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-for-weltruza-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSCH","LFSC","TEVA","MRNY","GDOC","BK4588","BK4566","BK4007","IYH","XLVX","BBP","BK4596","IDNA","MEDI","TECB","BMED","LABU","NVIB","BK4557","IBB","LU2324357040.USD","FRTY","BK4584","IEIH","SYNB","GNMX","TBXU","RSPH","LU1983299246.USD","PINK","BK4559","BK4585","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673079126","title":"Alkermes Plc : Leerink Partners Cuts Target Price to $45 from $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2673079126","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673079126?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:06","pubTimestamp":1791457599,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45U1FR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MEDX","IBRN","PSIL","FBT","BK4139","ALKS","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673023384","title":"Newron presses on with ENIGMA-TRS program as FDA clinical hold prompts safety review","url":"https://stock-news.laohu8.com/highlight/detail?id=2673023384","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673023384?lang=en_us&edition=fundamental","pubTime":"2026-10-08 13:32","pubTimestamp":1791437568,"startTime":"0","endTime":"0","summary":"An announcement from Newron Pharmaceuticals SpA ( ($CH:NWRN) ) is now available. Newron Pharmaceuticals has received a formal notification from the...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/newron-presses-on-with-enigma-trs-program-as-fda-clinical-hold-prompts-safety-review?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/newron-presses-on-with-enigma-trs-program-as-fda-clinical-hold-prompts-safety-review?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","MEDX","IBBQ","BBC","SYNB","IBB","BIS","PSCH","PILL","LABU","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673011796","title":"Alkermes Advances Adult ADHD Pipeline With New Phase 2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011796","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011796?lang=en_us&edition=fundamental","pubTime":"2026-10-08 00:30","pubTimestamp":1791390650,"startTime":"0","endTime":"0","summary":"Alkermes plc ($ALKS) announced an update on their ongoing clinical study. Alkermes plc (ALKS) is running a mid-stage clinical study to test a new A...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alkermes-advances-adult-adhd-pipeline-with-new-phase-2-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alkermes-advances-adult-adhd-pipeline-with-new-phase-2-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","ALKS","PSIL","MEDX","BK4139","IBRN","FBT","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673011517","title":"Novartis announces FDA approval of Rhapsido for symptomatic dermographism","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011517","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011517?lang=en_us&edition=fundamental","pubTime":"2026-10-07 23:50","pubTimestamp":1791388212,"startTime":"0","endTime":"0","summary":"Novartis (NVS) announced that the Food and Drug Administration approved Rhapsido as the first treatment for adults with symptomatic dermographism i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-announces-fda-approval-of-rhapsido-for-symptomatic-dermographism-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-announces-fda-approval-of-rhapsido-for-symptomatic-dermographism-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSCH","MEDX","LU0070302665.USD","XLVX","NVIB","LU0208291251.USD","IE00BJT1NW94.SGD","BMED","LFSC","IYH","LABU","FRTY","BK4585","BK4588","BBP","BK4007","MEDI","IEIH","TECB","GNMX","PINK","BK4578","MRNY","LU0320765489.SGD","IE0002141913.USD","IBB","SYNB","TBXU","GDOC","IDNA","BK4532","MRNX","IE00BFTCPJ56.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","LU0211331839.USD","RSPH","NVS","IE00BJJMRZ35.SGD","PPH","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673118620","title":"Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673118620","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673118620?lang=en_us&edition=fundamental","pubTime":"2026-10-07 23:45","pubTimestamp":1791387900,"startTime":"0","endTime":"0","summary":"In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21SD is most prevalent type of chronic inducible ur","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/07/3376686/0/en/novartis-rhapsido-remibrutinib-receives-fda-approval-as-first-treatment-for-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-csu.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IAI","LU1064131342.USD","LU1720051108.HKD","LU0210528500.USD","LU1668664300.SGD","LU0528227936.USD","LU0267386448.USD","MEDI","PINK","LU2089284900.SGD","PSCH","KBWB","LU2357305700.SGD","LU2487616109.SGD","SD","TBXU","TECB","BK4581","LFSC","MRNX","LABU","BK4585","LU1720051017.SGD","LU0390134368.USD","NVIB","FRTY","IBB","BK4504","LU0912757837.SGD","BBP","LU1791710582.SGD","IEIH","LU2028103732.USD","BMED","MRNY","XLVX","LU1244550221.USD","LU0795875169.SGD","SYNB","RSPH","LU2023251221.USD","GDOC","LU2264538146.SGD","IE00BZ1G4Q59.USD","LU0106831901.USD","IE00B3S45H60.SGD","LU1989772840.SGD","IYH","GNMX","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673808390","title":"Corcept Endocrinology President Sean Maduck Disposes of USD 2.89 Million in Corcept Therapeutics Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2673808390","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673808390?lang=en_us&edition=fundamental","pubTime":"2026-10-06 07:50","pubTimestamp":1791244214,"startTime":"0","endTime":"0","summary":"Corcept Endocrinology President Sean Maduck disposes of USD 2.89 million in Corcept Therapeutics sharesSean Maduck, President, Corcept Endocrinology, reported option exercises and share sales in Corce","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL7Q9kfn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Endocrinology President Sean Maduck Disposes of USD 2.89 Million in Corcept Therapeutics Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","BK4532","PSCH","CORT","BK4007","LU1559883803.SGD","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673308745","title":"Corcept Files Form 3 for President, Corcept Endocrinology Justin Gunn","url":"https://stock-news.laohu8.com/highlight/detail?id=2673308745","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673308745?lang=en_us&edition=fundamental","pubTime":"2026-10-06 07:18","pubTimestamp":1791242335,"startTime":"0","endTime":"0","summary":"Corcept files Form 3 for President, Corcept Endocrinology Justin GunnCorcept’s President, Corcept Endocrinology Justin Frederick Gunn filed a Form 3 showing 12,191 shares of common stock.Disclosure al","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL83wYZK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","BK4532","LU0566484027.USD","CORT","BK4007","FBT","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672263897","title":"Missed BrightSpring’s 112% Run? The Argument Behind It Still Holds Curiosity","url":"https://stock-news.laohu8.com/highlight/detail?id=2672263897","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672263897?lang=en_us&edition=fundamental","pubTime":"2026-10-03 21:22","pubTimestamp":1791033739,"startTime":"0","endTime":"0","summary":"If you had paused on 2 October 2025, looking at BrightSpring Health Services as analysts argued over margins, regulation, and aging demographics, the choice did not look simple. For BrightSpring Health Services shareholders, the return over the past year was 112.4%, including dividends. That outcome is now fixed. The real question is what early buyers were weighing back then about specialty pharmacy momentum, leverage, and government reimbursement risk before any of the later earnings...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6032000-choice2-card/1788952998790","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6032000-choice2-card/1788952998790"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-btsg/brightspring-health-services/news/missed-brightsprings-112-run-the-argument-behind-it-still-ho","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-btsg/brightspring-health-services/news/missed-brightsprings-112-run-the-argument-behind-it-still-ho","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4196","LU2468319806.SGD","PTH","LU2089984988.USD","LU2324357040.USD","PSCH","BTSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672974104","title":"Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $83,464.02","url":"https://stock-news.laohu8.com/highlight/detail?id=2672974104","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672974104?lang=en_us&edition=fundamental","pubTime":"2026-10-03 06:23","pubTimestamp":1790979782,"startTime":"0","endTime":"0","summary":"Alkermes EVP, CLO David Joseph Gaffin disposes of 2,034 common shares worth $83,464.02Alkermes EVP and chief legal officer David Joseph Gaffin sold 2,034 ordinary shares on Oct. 2, 2026.Sale price USD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL6fSlzc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $83,464.02","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS","PSIL","MEDX","BK4139","IBRN","FBT","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672235796","title":"Alkermes (ALKS), What Is Behind The Fresh Attention?","url":"https://stock-news.laohu8.com/highlight/detail?id=2672235796","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672235796?lang=en_us&edition=fundamental","pubTime":"2026-10-02 09:21","pubTimestamp":1790904114,"startTime":"0","endTime":"0","summary":"Alkermes (NasdaqGS:ALKS) is back on investors’ radar after releasing phase 1 proof of concept data for ALKS 7290 in adults with ADHD, showing clinically meaningful symptom improvements and supportive safety findings.\nRecent trading tells a mixed story for Alkermes. The share price is around $40.54, with a 30 day share price return down 14.11% and a 90 day move lower by 25.72%. Yet the year to date share price return is up 43.45% and the 1 year total shareholder return sits at 29.69%,...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/alkermes-alks-what-is-behind-the-fresh-attention","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/alkermes-alks-what-is-behind-the-fresh-attention","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","IBRN","MEDX","FBT","ALKS","PSCH","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672475403","title":"BrightSpring Health Updates Financial Calendar for Third-Quarter 2026 Results Release and Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2672475403","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672475403?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:05","pubTimestamp":1790856336,"startTime":"0","endTime":"0","summary":"BrightSpring Health updates financial calendar for third-quarter 2026 results release and callBrightSpring Health Services schedules its third-quarter 2026 earnings release for Oct. 30, 2026.Earnings ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDLs3mT9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","LU2210149790.SGD","IE00BQXX3C00.GBP","IE00BQXX3F31.USD","IE00BN0W2V16.EUR","BCDF","PSCH","IE00BGHQF748.EUR","SG9999014021.USD","IE00BN0W2T93.GBP","LU2089984988.USD","NDAQ","SG9999014039.USD","LU2324357040.USD","IE00BN0W2W23.USD","BTSG","LU2210150020.SGD","BK4588","BK4112","LU2095319765.USD","IE00BKPKM429.USD","PTH","LU0314104364.USD","BK4196","IE00B64PRP62.GBP","SG9999014013.SGD","BK4585","SG9999014005.SGD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671125702","title":"Teva announces FDA approval of Degevma as a biosimilar to Xgeva","url":"https://stock-news.laohu8.com/highlight/detail?id=2671125702","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671125702?lang=en_us&edition=fundamental","pubTime":"2026-09-29 04:05","pubTimestamp":1790625914,"startTime":"0","endTime":"0","summary":"Teva (TEVA) Pharmaceutical Industries announced that the FDA has approved Degevma as a biosimilar to Xgeva. Degevma is indicated for the prevention...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4566","FRTY","BK4585","BK4559","MRNX","IDNA","XLVX","IBB","MEDI","BK4557","BBP","LU1983299246.USD","BK4007","RSPH","LABU","IYH","LU2324357040.USD","TBXU","LFSC","PSCH","BMED","TECB","TEVA","IEIH","GNMX","BK4588","BK4584","GDOC","SYNB","MRNY","PINK","NVIB","BK4596"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670236928","title":"Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M","url":"https://stock-news.laohu8.com/highlight/detail?id=2670236928","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670236928?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:10","pubTimestamp":1790590220,"startTime":"0","endTime":"0","summary":"With the completion of the Theravance Biopharma acquisition and the receipt of the U.S. FDA approval of Ziihera for first-line HER2-positive advanc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zymeworks-sees-fy26-revenue-278m-292m-consensus-304-04m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zymeworks-sees-fy26-revenue-278m-292m-consensus-304-04m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNMX","BK4588","TECB","LABU","MRNX","XLVX","TBXU","PSCH","BK4007","PINK","GDOC","IEIH","BK4585","IYH","BMED","RSPH","LFSC","TBPH","BBP","MEDI","IBB","NVIB","SYNB","MRNY","FRTY","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670246233","title":"Court Dismisses Molina Healthcare Securities Fraud Complaint, Allows Plaintiff to Amend","url":"https://stock-news.laohu8.com/highlight/detail?id=2670246233","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670246233?lang=en_us&edition=fundamental","pubTime":"2026-09-28 17:26","pubTimestamp":1790587564,"startTime":"0","endTime":"0","summary":"A federal judge has dismissed the consolidated securities fraud complaint against Molina Healthcare ($MOH) and two of its executives, while allowin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/court-dismisses-molina-healthcare-securities-fraud-complaint-allows-plaintiff-to-amend?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/court-dismisses-molina-healthcare-securities-fraud-complaint-allows-plaintiff-to-amend?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","SG9999014039.USD","BK4588","XLV","PSCH","LABU","BK4154","SG9999014013.SGD","SG9999014021.USD","BK4581","BK4532","SG9999014005.SGD","MOH","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670402990","title":"EBR Systems advances FDA approval process for new WiSE manufacturing site","url":"https://stock-news.laohu8.com/highlight/detail?id=2670402990","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670402990?lang=en_us&edition=fundamental","pubTime":"2026-09-28 08:08","pubTimestamp":1790554084,"startTime":"0","endTime":"0","summary":"The latest announcement is out from EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:EBR) ). EBR Systems, developer of the WiSE wi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ebr-systems-advances-fda-approval-process-for-new-wise-manufacturing-site?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ebr-systems-advances-fda-approval-process-for-new-wise-manufacturing-site?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNY","LABU","FRTY","LFSC","IYH","PSCH","BBP","SYNB","IBB","XLVX","BK4588","TBXU","PINK","MEDI","BK4585","TECB","BMED","NVIB","GNMX","MRNX","RSPH","IEIH","GDOC","EES","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669460339","title":"Alkermes (ALKS) Gets a Hold from Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2669460339","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669460339?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:45","pubTimestamp":1790250329,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst Andrea Newkirk resumed coverage with a Hold rating on Alkermes today and set a price target of $50.00. According to TipRanks,...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alkermes-alks-gets-a-hold-from-goldman-sachs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alkermes-alks-gets-a-hold-from-goldman-sachs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBRN","BK4585","LU2237443895.HKD","LU1791807156.HKD","LU0345770308.USD","ALKS","LU1868836591.USD","LU2237438978.USD","LU2471134796.USD","LU2896262040.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4550","LU1668664300.SGD","LU1144417596.USD","LU0868494708.USD","LU2471134879.HKD","BK4552","FBT","LU2471134523.USD","LU0210536198.USD","LU1868837300.USD","LU0868494617.USD","LU2750360641.GBP","GSX","IE0004091025.USD","LU1868836757.USD","LU2265009873.SGD","PSCH","BK4127","IE0034235188.USD","IE00BSNM7G36.USD","IE0002270589.USD","LU2237443465.HKD","PSIL","LU2237443978.SGD","LU2237443622.USD","BK4516","LU0251131958.USD","BK4533","IE0004086264.USD","LU1894683264.USD","LU2471134952.CNY","MEDX","BK4588","BK4504","LU1894683348.USD","LU1868837136.USD","LU0742534661.SGD","LU1804176565.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669437128","title":"Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches","url":"https://stock-news.laohu8.com/highlight/detail?id=2669437128","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669437128?lang=en_us&edition=fundamental","pubTime":"2026-09-24 08:30","pubTimestamp":1790209807,"startTime":"0","endTime":"0","summary":"An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast has secured U.S. FDA approval for a new T-cell Proliferation Inhib...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-wins-fda-nod-for-new-potency-assay-on-ryoncil-batches?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-wins-fda-nod-for-new-potency-assay-on-ryoncil-batches?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","LABU","NVIB","IDNA","BK4139","LFSC","MEDI","MRNY","GNMX","RSPH","IEIH","MESO","FRTY","MRNX","GDOC","TBXU","XLVX","BBP","BK4588","PSCH","PINK","SYNB","IYH","BK4585","BMED","TECB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669448936","title":"Corcept Therapeutics Announces New Endocrinology Division President","url":"https://stock-news.laohu8.com/highlight/detail?id=2669448936","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669448936?lang=en_us&edition=fundamental","pubTime":"2026-09-23 21:01","pubTimestamp":1790168500,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics ( ($CORT) ) has shared an announcement. On September 22, 2026, Corcept Therapeutics said Sean Maduck, president of its Endocri...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/corcept-therapeutics-announces-new-endocrinology-division-president?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/corcept-therapeutics-announces-new-endocrinology-division-president?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0566484027.USD","LU1559883803.SGD","BK4532","CORT","BK4007","FBT","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669459483","title":"Corcept Names Justin Gunn President of Endocrinology as Sean Maduck Retires","url":"https://stock-news.laohu8.com/highlight/detail?id=2669459483","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669459483?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:02","pubTimestamp":1790164960,"startTime":"0","endTime":"0","summary":"Corcept names Justin Gunn president of endocrinology as Sean Maduck retiresCorcept named Justin Gunn president of its Endocrinology division, effective Oct. 1, succeeding retiring Sean Maduck.Gunn wil","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL6My5bl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0566484027.USD","LU1559883803.SGD","CORT","FBT","BK4007","PSCH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}